Biologic therapy in clinical practice: Enthusiasm must be tempered by caution

Rheumatology

Volumn 42, Issue 5, 2003, Pages 614-616

  Moots, R J ^a   Taggart, A ^b   Walker, D ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MUSGRAVE PARK HOSPITAL   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; INFECTION; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUMOR; BIOLOGICAL THERAPY; CHEMICALLY INDUCED DISORDER; IMMUNE DEFICIENCY; IMMUNOLOGY; OPPORTUNISTIC INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS;

EID: 0141615957     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Causes of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
2. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11:158-61.
3. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DA, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
4. Markenson JA. Worldwide trends in the socio-economic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum 1991;21(Suppl. 1):4-12.
5. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
6. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
7. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
8. Klareskog L, Moreland LM, Cohen SB, Sanda M, Burge DJ. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy in rheumatoid arthritis. Arthritis Rheum 2001;44 (Suppl.):S77.
9. Kavanaugh A, Keenan G, DeWoody K et al. Long-term follow-up of patients treated with remicade (infliximab) in clinical trials. Arthritis Rheum 2001;44(Suppl.):S81.
10. National Institute of Clinical Excellence. NICE Technology Appraisal Guidance - No. 36. Guidance on the use of etanercept and infliximab for the treatment rheumatoid arthritis. London: National Institute of Clinical Excellence, 2002.
11. British Society for Rheumatology. Guidelines for prescribing TNF blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology, London: British Society for Rheumatology, 2000. 12 Marshall N, Young Min S, Smith AM, Kay L. Six months experience of a regional antiTNF therapy register in North East England. Rheumatology 2002;41(Suppl. 1):75.
12. Cairns AP, Patton J, Gardiner P et al. The use of biological agents for severe inflammatory arthritis in Northern Ireland. Rheumatology 2002;41(Suppl. 1):92.
13. Estrach C, Moots RJ, Dawson JK et al. Anti TNF therapy in real life: the Merseyside experience. Rheumatology 2002;41(Suppl. 1):92.
14. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
15. Estrach C, Moots RJ, Andrews S, Williams D, Sykes HR, Dawson JK. High incidence of pneumonia in patients on anti-TNF therapy. Rheumatology 2002;41(Suppl. 1):93.
16. Maksymowych WP, Mallon C, Spady B, Peerani R. The Alberta Capital Health Region Infliximab in Rheumatoid Arthritis Prospective Observational Inception Cohort: efficacy, adverse events and withdrawal. Arthritis Rheum 2001;44(Suppl.):S82.
17. Durez P, Devogelaer JP, Van den Bosch F et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: clinical results in a Belgian observational cohort. Arthritis Rheum 2001;44(Suppl.):S83.
18. Antoni CE, Dechant C, Haentzschel H et al. Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis (RA) despite methotrexate therapy: a German open label trial. Arthritis Rheum 2001;44(Suppl.):S84.
19. Belostocki KB, Leibowitz E, Tai K, Harrison MJ. Infections associated with etanercept treatment for rheumatoid arthritis: 2 years of experience in the 'real-world'. Arthritis Rheum 2001;44(Suppl.):S173.
20. Anonymous. Infliximab (Remicade) and tuberculosis. Current Problems Pharmacovigilance 2001;27:7.
21. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. Infections in rheumatoid arthritis. Arthritis Rheum 2001; 44(Suppl.): S167.
22. Carmona L, Gonzales-Alvaro I, Sanmarti R et al. Rheumatoid arthritis is associated to a four-fold increase in tuberculosis infection incidence in the pre-biologics era. Arthritis Rheum 2001;44(Suppl.):S173.
23. Singh G, Ramey DR, Rausch PI, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use. Arthritis Rheum 1999;42(Suppl.):S242.
24. Sabath DF, Holman J, Wallis WJ et al. Serious infection reports with etanercept (Enbrel) therapy. Ann Rheum Dis 2002;(Suppl. 1):39.